These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 35584813)

  • 1. The Lard Works in Mysterious Ways: Ceramides in Nutrition-Linked Chronic Disease.
    Nicholson RJ; Norris MK; Poss AM; Holland WL; Summers SA
    Annu Rev Nutr; 2022 Aug; 42():115-144. PubMed ID: 35584813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceramides - Lipotoxic Inducers of Metabolic Disorders.
    Chaurasia B; Summers SA
    Trends Endocrinol Metab; 2015 Oct; 26(10):538-550. PubMed ID: 26412155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceramides in Metabolism: Key Lipotoxic Players.
    Chaurasia B; Summers SA
    Annu Rev Physiol; 2021 Feb; 83():303-330. PubMed ID: 33158378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of specific ceramides to obesity-associated metabolic diseases.
    Hammerschmidt P; Brüning JC
    Cell Mol Life Sci; 2022 Jul; 79(8):395. PubMed ID: 35789435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Phytochemicals in Obesity-Related Metabolic Diseases: Focus on Ceramide Metabolism.
    Kim E; Jeon S
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
    Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
    Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipids as a Culprit of Mitochondrial Dysfunction in Insulin Resistance and Type 2 Diabetes.
    Roszczyc-Owsiejczuk K; Zabielski P
    Front Endocrinol (Lausanne); 2021; 12():635175. PubMed ID: 33815291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotten to the Cortex: Ceramide-Mediated Lipotoxicity in Diabetic Kidney Disease.
    Nicholson RJ; Pezzolesi MG; Summers SA
    Front Endocrinol (Lausanne); 2020; 11():622692. PubMed ID: 33584550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceramides are fuel gauges on the drive to cardiometabolic disease.
    Wilkerson JL; Tatum SM; Holland WL; Summers SA
    Physiol Rev; 2024 Jul; 104(3):1061-1119. PubMed ID: 38300524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A ceramide-centric view of insulin resistance.
    Chavez JA; Summers SA
    Cell Metab; 2012 May; 15(5):585-94. PubMed ID: 22560211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceramides are necessary and sufficient for diet-induced impairment of thermogenic adipocytes.
    Chaurasia B; Ying L; Talbot CL; Maschek JA; Cox J; Schuchman EH; Hirabayashi Y; Holland WL; Summers SA
    Mol Metab; 2021 Mar; 45():101145. PubMed ID: 33352310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells.
    Bandet CL; Tan-Chen S; Bourron O; Le Stunff H; Hajduch E
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramide Acyl Chain Length and Its Relevance to Intracellular Lipid Regulation.
    Ho QWC; Zheng X; Ali Y
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms.
    Chavez JA; Summers SA
    Biochim Biophys Acta; 2010 Mar; 1801(3):252-65. PubMed ID: 19796706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
    Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
    Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceramides and other sphingolipids as drivers of cardiovascular disease.
    Choi RH; Tatum SM; Symons JD; Summers SA; Holland WL
    Nat Rev Cardiol; 2021 Oct; 18(10):701-711. PubMed ID: 33772258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin.
    Tong M; Longato L; Ramirez T; Zabala V; Wands JR; de la Monte SM
    Int J Exp Pathol; 2014 Feb; 95(1):49-63. PubMed ID: 24456332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
    Holland WL; Summers SA
    Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceramides in insulin resistance and lipotoxicity.
    Summers SA
    Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ceramide metabolism in obesity.
    Aburasayn H; Al Batran R; Ussher JR
    Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E423-35. PubMed ID: 27382035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.